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Large C9orf72 Hexanucleotide Repeat Expansions Are
Seen in Multiple Neurodegenerative Syndromes and
Are More Frequent Than Expected in the UK Population
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Andrea Malaspina,7 James Rowe,5 Jeremy Brown,5 John Hodges,5,9,10 Katie Sidle,4 James M. Polke,8
Henry Houlden,4,8 Jonathan M. Schott,3 Nick C. Fox,3 Martin N. Rossor,3 Sarah J. Tabrizi,2
Adrian M. Isaacs,2 John Hardy,4 Jason D. Warren,3 John Collinge,1 and Simon Mead1,*
Hexanucleotide repeat expansions in C9orf72 are a major cause of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral
sclerosis (ALS). Understanding the disease mechanisms and a method for clinical diagnostic genotyping have been hindered because
of the difficulty in estimating the expansion size. We found 96 repeat-primed PCR expansions: 85/2,974 in six neurodegenerative
diseases cohorts (FTLD, ALS, Alzheimer disease, sporadic Creutzfeldt-Jakob disease, Huntington disease-like syndrome, and other
nonspecific neurodegenerative disease syndromes) and 11/7,579 (0.15%) in UK 1958 birth cohort (58BC) controls. With the use of
a modified Southern blot method, the estimated expansion range (smear maxima) in cases was 800–4,400. Similarly, large expansions
were detected in the population controls. Differences in expansion size and morphology were detected between DNA samples from
tissue and cell lines. Of those in whom repeat-primed PCR detected expansions, 68/69 were confirmed by blotting, which was specific
for greater than 275 repeats.We found thatmorphology in the expansion smear varied among different individuals and among different
brain regions in the same individual. Expansion size correlated with age at clinical onset but did not differ between diagnostic groups.
Evidence of instability of repeat size in control families, as well as neighboring SNP and microsatellite analyses, support multiple expan-
sion events on the same haplotype background. Our method of estimating the size of large expansions has potential clinical utility.
C9orf72-related disease might mimic several neurodegenerative disorders and, with potentially 90,000 carriers in the United Kingdom,
is more common than previously realized.Introduction
Large expansions of a noncoding GGGGCC repeat in
C9orf72 have recently been identified as a leading cause of
frontotemporal lobar degeneration (FTLD [MIM 600274]),
amyotrophic lateral sclerosis (ALS [MIM 612069]), and
the combined syndrome, FTLD-ALS.1–3 The finding is
remarkable because of the high mutation prevalence in
these disease syndromes and because the nature of the
mutation implies a distinct mechanism of neurodegenera-
tion. The discovery of the causal mutation and its further
investigation have been hampered by the extremely large
size of the expansion, which prevents amplification of the
entire expansion by conventional PCR-based methods.
Southern blotting has been used for approximating the
true repeat size in one small series of individuals,2 so little
is known about the pathogenic size range, mutationmech-
anisms, feasibility and accuracy of diagnostic testing, and
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The AmeDNA from the expansion allele can be amplified by
PCR with primers complementary to the repeat (repeat-
primed PCR [rpPCR]); however, this method cannot size
accurately beyond around 30 repeats.1 In a large series
screened with the rpPCR-based method, mutations were
found in 8% of ALS simplex cases (39% of familial ALS)
and 7% of FTLD simplex cases (25% of familial FTLD).4
The phenotype associated with the expansion might
extend beyond FTLD and ALS, but it is difficult to
make this conclusion before the repeat size at which
the mutation becomes pathogenic in different clinical
syndromes is understood. Thus, aside from FTLD and
ALS cases, mutations with >32 repeats have also been
reported in healthy individuals,1,5 as well as in those
affected by Alzheimer disease (AD)6 and corticobasal7,8
and ataxic syndromes.8 The prominence of psychiatric
and amnestic symptoms in individuals with FTLD
and/or ALS is a potential factor leading to diagnostic
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There are also important outstanding questions about
mutationmechanisms. A single ancestral mutational event
explaining all or the large majority of cases has been
proposed because of the high prevalence of C9orf72 ex-
pansions in Finland and because mutation cases share
a haplotype on the adjoining region of chromosome 9.10
An alternative hypothesis is that multiple unrelated
mutational events occurred on the same SNP haplotype
background as a result of a premutation allele that confers
increased risk of developing a huge expansion.4,5,10,11
Here, we sought to resolve some of the outstanding
genetic issues by developing a Southern blot methodology
and evaluating this method by estimating expansion size
in a large proportion of cases identified from a screen of
the archives of a United Kingdom (UK) national referral
center. Further, we capitalized on long-term cohort studies
to characterize the population prevalence of large muta-
tions and make inferences regarding mutational mecha-
nisms and phenotypic heterogeneity.Material and Methods
Statistics were done with the IBM SPSS Statistics 19 package.
Ethical approval was obtained from the National Hospital for
Neurology and Neurosurgery Research Ethics Committee.
Informed consent for genetic studies was obtained from all partic-
ipants. For methods of SNP and microsatellite genotyping, see the
Supplemental Data, available online.Southern Blotting
gDNA was digested overnight with AluI (20 u) and DdeI (20 u)
prior to electrophoresis. DNAwas transferred to positively charged
nylon membrane (Roche Applied Science) by capillary blotting
and was baked at 80C for 2 hr. The hybridization probe was an
oligonucleotide from Eurofins MWG Operon (Germany) and
comprised five hexanucleotide repeats (GGGGCC)5 labeled 3
0
and 50 with digoxigenin (DIG). Filter hybridization was under-
taken as recommended in the DIG Application Manual (Roche
Applied Science) except for the supplementation of DIG Easy
Hyb buffer with 100 mg/ml denatured fragmented salmon sperm
DNA. After prehybridization at 48C for 4 hr, hybridization was
allowed to proceed at 48C overnight. A total of 1 ng of labeled
oligonucleotide probe was used permilliliter of hybridization solu-
tion. Membranes were washed initially in 23 standard sodium
citrate (SSC) and 0.1% sodium dodecyl sulfate (SDS) while the
oven was being ramped from 48C to 65C and then washed in
fresh solution at 65C for 15 min; further 15 min washes in
0.53 SSC, 0.1% SDS and 0.23 SSC, and 0.1% SDS at 65C fol-
lowed. Detection of the hybridized probe DNA was carried out as
recommended in the DIG Application Manual with CSPD ready-
to-use (Roche Applied Science) as a chemiluminescent substrate.
Signals were visualized on Fluorescent Detection Film (Roche
Applied Science) after 1–5 hr. All samples were electrophoresed
against DIG-labeled DNA molecular-weight markers II and VII
(Roche Applied Science). Hexanucleotide repeat number was
estimated by visual interpolation with a plot (created in Microsoft
Excel) of log10 base-pair number against migration distance and
subtraction of the wild-type allele fragment size (199 bp).
Maximum, minimum, and modal sizes were recorded for each346 The American Journal of Human Genetics 92, 345–353, March 7individual with expanded repeats. No signal from the pathogenic
range was observed with this method in 50 rpPCR samples in
which no expansion > 32 repeats was detected.Assessment of Hexanucleotide Repeat Number
Variation in the hexanucleotide repeat number was assessed in
one of two ways. First, rpPCR was carried out largely as previously
described.1 Expansions with a characteristic ‘‘saw-tooth’’ pattern
were identified and put forward for Southern blotting where suffi-
cient DNA allowed. Peaks were counted, and the first peak repre-
sented two repeats. Peak intensity was used for identifying
zygosity, where homozygous samples had no obvious step in the
stutter pattern, whereas a decline of about one-half was indicative
of heterozygosity. Second, fluorescent-labeled PCR was followed
by fragment-length analysis on an ABI 3730xl automated
sequencer. The PCR used 20 ng gDNA in FastStart PCR master
mix (Roche Applied Science) supplemented with 13 Q solution
(Roche Applied Science), 5% dimethyl sulphoxide, 0.2 mM
7-deaza-2-deoxy guanosine triphosphate, and 1 mM MgCl2 in
a 20 ml final volume. Thermal cycling included initial denaturation
for 5 min and 35 subsequent cycles of 30 s denaturation at 95C,
30 s annealing at 60C, and 1 min elongation at 72C.Samples
Individual samples for mutation screening were identified from
the Medical Research Council (MRC) Prion Unit research sample
database, which has recorded samples referred for clinical diag-
nosis or research since 1990. Other referral series included samples
held at the Department of Molecular Neuroscience at the
University College London Institute of Neurology (Huntington
disease [HD]-like syndrome), National Hospital for Neurology
and Neurosurgery (ALS), North-East London and Essex Regional
MND Care Centre (ALS), and Department of Clinical Neurosci-
ences at Cambridge University (FTLD). The MRC Prion Unit
receives samples from individuals with suspected prion disease,
AD, FTLD, ALS, Huntington disease, and other neurodegenerative
disorders that might mimic these conditions. Some of these
individuals are enrolled in systematic observational cohort studies
with associated high levels of diagnostic scrutiny according to
recognized criteria (for example, the National Prion Monitoring
Cohort study, the University College London [UCL] FTLD DNA
cohort, and the UCL familial Alzheimer disease DNA cohort),
whereas other samples were referred to the MRC Prion Unit by
UK neurologists for research genetic studies after diagnoses were
made according to local practices. Samples from individuals
thought to have HDbut negative for this disease upon gene testing
were derived from the archives of the UCL Department of
Molecular Neuroscience after referral with suspected HD from
HD expansion testing; these samples largely comprise those
from individuals seen at the Huntington’s Disease Multidisci-
plinary Clinic, National Hospital for Neurology and Neurosurgery,
Queen Square. The sample cohorts investigated were therefore
heterogeneous in the use of established diagnostic criteria; after
the finding of a C9orf72 expansion in a sample, clinical case notes
were reviewed and original clinical diagnosis were revised if neces-
sary. Control samples were obtained from the Fondation Jean
Dausset-Centre d’Etude du Polymorphisme Humain (CEPH), the
European Collection of Cell Cultures (ECACC) Human Random
Control DNA Panels 1–5, and the 1958 Birth Cohort (58BC)
(University of Leicester). Samples with multiple brain tissues
were provided by the Queen Square Brain Bank., 2013
Table 1. Frequency of Large C9orf72 Expansions in Cases and Controls
Cases Controls
FTLD ALS
Other Neurodegenerative
Disease sCJD AD
HD-like
Syndrome All Cases ECACC
1958 Birth
Cohort All Controls
Total screened 375 360 444 470 904 421 2,974 474 7,105 7,579
Expansion detected
by rpPCR
28 29 9 1 11 7 85 2 9 11
Frequency 0.075 0.081 0.02 0.002 0.012 0.017 0.029 0.004 0.001 0.0015
Expansion confirmed
by Southern blotting
17/17 19/19 6/7a 1/1 8/8 6/6 57/58 2/2 9/9 11/11
Details of the study cohort show the total number of cases and controls screened by rpPCR and the number of C9orf72 expansions detected in each cohort and
their frequency. The subset of those in whom rpPCR detected expansions > 32 repeats and who were then screened by Southern blotting are also shown. The
following abbreviations are used: FTLD, frontotemporal lobar degeneration; ALS, amyotrophic lateral sclerosis; sCJD, sporadic Creutzfeldt-Jakob disease; AD,
Alzheimer disease; HD, Huntington disease; ECACC, European Collection of Cell Cultures; and rpPCR, repeat-primed PCR.
aOne case with an apparent expansion of 80þ repeats by rpPCR did not show large expansion by Southern blotting, although there was not enough material for
repeat analysis.Results
A total of 2,974 individuals composed six disease cohorts
(FTLD, AD, ALS, sporadic Creutzfeldt-Jakob disease [sCJD]
[simplex cases with CJD], HD-like syndrome, or other
neurodegenerative diseases). The purpose of the extended
screen of individuals was to characterize the phenotypic
range and provide varied case samples for subsequent
genotype-phenotype correlation. The number of rpPCR
individual samples estimated to have >32 repeats was
28/375 (7.5%) for FTLD, 11/904 (1.2%) for AD, 29/360
(8.1%) for ALS, 1/470 (0.2%) for sCJD, 9/444 (2.0%) for
other neurodegenerative diseases, and 7/421 (1.7%) for
HD-like syndrome for a total of 85 C9orf72 expansion
samples (two samples were identified retrospectively to
be in the cohorts for both HD-like syndrome and FLTD
and were removed from the former category). Eighteen
FTLD cases from the UCL FTLD DNA cohort have been
described in detail elsewhere but are included here for
comparison purposes.9 Mean age of onset was 54.6 years
and did not differ between cohorts; an autosomal-
dominant inheritance pattern of early-onset neurodegen-
erative disease (at least one other relative) was documented
in 29%. Notable atypical clinical presentations and/or
features included psychiatric symptoms (treatment with
major tranquilizers in at least three) and movement
disorders (Parkinsonism in two, chorea in several in the
HD-like-syndrome cohort, and myoclonus prompting
consideration of CJD in one). Upon review of the case
notes from the AD series, in which more details were avail-
able, C9orf72 cases had clinical features that overlapped
those of FLTD, suggesting that diagnostic overlap between
AD and FTLD might explain the finding of expansions in
the AD cohort; there were no autopsy findings available.
To determine the frequency of C9orf72 expansion in
the healthy control population, we also performed rpPCR
in the 58BC (Table 1). Because individuals in this cohort
are now 54 years old, we performed a retrospective case
review to exclude individuals with a clinical diagnosis.The AmeAfter excluding one individual with ALS, we determined
that the prevalence of the C9orf72 expansion in the
control population was 11/7,598 (1 in 691 or 0.15%
[95% confidence interval 0.07%–0.26%]). In case-control
comparison, as expected, an expansion > 32 repeats was
associated with FTLD and ALS (p < 1028, Fisher’s exact
test), AD (p ¼ 4.3 3 106), HD-like syndrome (p ¼ 2 3
105), and other neurodegenerative diseases (p ¼ 4.3 3
107), but not CJD.
We then looked at the stability of the C9orf72 hexanu-
cleotide repeat region in the CEPH family series (Tables
S1 and S2). No large expansions (>32 repeats) were identi-
fied via rpPCR. However, in 1,046 transmissions, three
changes in repeat size between generations were identified.
In the CEPH families, the largest repeat (22 repeats)
changed size twice in the same family: from 21 in the
paternal grandparent to 22 in the father and from 22 in
the father to 20 in the son (Table S2). There were no
unstable maternal transmissions. The overall intergenera-
tional repeat change rate was 0.29%. Interestingly, all
intergenerational changes occurred from a starting repeat
length > 10. These changes were verified by repeat rpPCR
and fluorescent-labeled PCR size fractionation (although
we cannot exclude alteration of flanking sequences).
To determine whether there was a specific haplotype on
which the intergenerational repeat changes in the CEPH
family occurred, we genotyped neighboring SNPs and
microsatellites and empirically determined haplotypes
by using family data. All intergenerational changes
occurred on the same haplotype, which we named the
rs3849942A haplotype. The shared haplotype and the
larger starting repeat length (but within the normal range),
support the inference that either one or both of these
features might confer instability of repeat length.
As reported by others, we found strong linkage disequi-
librium (LD) between repeat length and a neighboring
SNP, rs3849942 (see Figure 1).4,5,10 A total of 5,200
Wellcome Trust Case Control Consortium 2 control
individuals were assessed with fastPHASE, generatingrican Journal of Human Genetics 92, 345–353, March 7, 2013 347
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Figure 1. Histogram of C9orf72 Repeat
Size in the Healthy Population
Histogram showing frequency of C9orf72
repeat sizes from 1–32 in 58BC UK
controls and the entire CEPH collection.
rs3849942G-associated repeats are shown
in green, and those associated with
rs3849942A (‘‘risk’’ haplotype marker) are
shown in red. The phase of genotypes
with repeat size was calculated for the
CEPH individuals, and frequencies were
then applied to the 58BC data.haplotypes across chromosome 9 region 27,471,905–
27,562,634 (~91 kb). Of 10,400 haplotypes, 2,597 (25%)
were rs3849942A. Of the 2,597 rs3849942A haplotypes
we detected, 2,435 (94%) were identical to each other and
the disease-related haplotype described by Mok et al.10
The disease-associated SNP haplotype is therefore common
in the UK population.
The outstanding question is whether all cases share an
ancient common ancestor or whether the rs3849942A
haplotype confers increased risk of mutation. We sought
to distinguish these possibilities by testing for evidence
of recent shared ancestry between cases diagnosed in one
region by looking at ten microsatellites over 13.1 Mb
surrounding C9orf72 (two microsatellites were within
300 kb of C9orf72). The moment an expansion mutation
occurs, it is linked with all microsatellite variation on the
same chromosome; however, over subsequent generations,
this mutation-associated haplotype breaks down as a result
of both recombination occurring between C9orf72 and
the microsatellite and alteration of the microsatellite
repeat length by mutation. We found eight different
microsatellite alleles linked to C9orf72 expansions at two
microsatellites within 300 kb; they had an estimated
recombination rate with C9orf72 of less than once in 100
generations.12 We empirically estimated the total number
of possible microsatellite haplotypes in a subset of 48348 The American Journal of Human Genetics 92, 345–353, March 7, 2013expansion cases for whom complete
haplotype data existed. We found at
least 60 different haplotypes on the
basis of the incompatibility of geno-
types. Using the same empirical
methods, we made similar estimates
in 48 CEPH parents and predicted at
least 76 haplotypes (not statistically
significantly different from those of
the cases). Haplotyping using geno-
types from children of the same
CEPH parents revealed that all 96
haplotypes were unique, implying
that all or a very high proportion of
haplotypes in the case series were
also unique. The microsatellite allele
frequencies associated with C9orf72
expansions as a group were indistin-guishable from those of controls, including those linked
with rs3849942A (Table S1). These data provide strong
evidence against recent shared ancestry of a large propor-
tion of C9orf72 expansion individuals in the UK.
We modified the Southern blotting method of DeJesus-
Hernandez et al.2 with the aim of enhancing the expan-
sion signal (see Material and Methods and Figures 2–4)
by using a more complete restriction-endonuclease diges-
tion of genomic DNA and a (GGGGCC)5 DIG probe rather
than one specific to adjacent DNA sequence. A more sensi-
tive blotting methodology would allow direct estimates of
document size ranges (smears) and expansion size in a large
and more representative sample series and would allow
genotype-phenotype correlations. We found no large ex-
pansions in 50 of those in whom rpPCR did not detect
mutations> 32 repeats (Figure S2), and we confirmed large
expansions in 68/69 of those in whom rpPCR did detect
expansions, demonstrating the high specificity of the
modified protocol (Figure S3). We were unable to retest
the single sample in which the Southern blot did not
confirm a large expansion because of a lack of material.
Out of the 68 of those in whom rpPCR detected expan-
sions > 32 repeats, 67 gave patterns of varying forms of
long smears interrupted by one or more modal points
(see Figures 2–4 for individual estimates of repeat size).
The blot of the remaining individual did not manifest as
1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500
HD-like
syndrome
Figure 2. Schematic of Southern Blotting Data for Large C9orf72 Repeat Expansions
A schematic of Southern blot data for 57 cases and 11 controls shows C9orf72 repeats sizes across seven cohorts. Individual blot data are
represented by colored bars, modes are indicated by similarly colored dots, and the midpoint of size is represented by a vertical black
bar. Ages of onset, when available, are given in years at the right-hand end of individual bars. DNAwas extracted from tissues, as shown
on the left. In three controls, data are shown for DNA extracted from a lymphocyte cell line (LCL) and peripheral blood (blood).
Brackets indicate that two adjacent bars are from the same individual. A single asterisk indicates an unusual ALS case with a doublet
of bands of relatively low size, and double asterisks indicate a single 58BC individual with a large repeat size from LCL DNA and
a diagnosis of ALS.a smear but as two distinct bands (Figure S4). For statistical
analysis, we compared multiple estimates of repeat size on
the basis of smear maxima (range 790–4,400) and minima
(400–1,500), smear midpoint (700–3,000), and mode
(630–3,800) or modal points (630–2,200; 20 samples had
more than one mode). DNA from lymphocyte cell lines
(LCLs) was associated with smaller repeats sizes and
a distinct multimodal banding pattern (Figures 3 and 4),
which we assumed relates to the pauciclonal origins of
DNA in cell lines. Surprisingly, all of the control partici-
pants in whom rpPCR detected expansions > 32 repeats
had large expansions (>400 repeat smear minima) andThe Ameoverlapped the range seen in cases. Three control samples
were available from blood, and all were typical of cases
(Figure 4).
Minima, maxima, midpoint, and modal estimates of
repeat size were all statistically significantly correlated
with some aspects of clinical phenotype; however, impor-
tantly, there were no differences between any two disease
cohorts by any measure of repeat size (p > 0.1 for all pair-
wise comparisons, Tukey’s post hoc test, ANOVA). Repeat
sizes of LCL DNA (largely controls) were smaller than those
of blood-extracted DNA by all measures (p < 0.01, Tukey’s
post hoc test, ANOVA). The modal point of repeat sizerican Journal of Human Genetics 92, 345–353, March 7, 2013 349
Figure 3. Example Southern Blots of
Various Large C9orf72 Repeat Expansions
A Southern blot showing C9orf72 repeat
expansions in eight cases and one ECACC
control and two 58BC controls demon-
strates typical banding patterns and lower
size in LCL DNA than in peripheral-blood
DNA. Control DNA without an expan-
sion is also shown. Cases 1 and 2 show
Southern blotting of DNA from three
different brain regions. The asterisk in-
dicates GGGGCC containing a short-
tandem-repeat genome motif unrelated
to C9orf72. The missing bands in case 1
(brain stem) is most likely due to a reduced
amount of gDNA.correlated with age at clinical onset (increasing age,
increasing repeat size, Pearson correlation 0.38, p ¼
0.02); however, other repeat-size metrics did not signifi-
cantly correlate. In two cases, we blotted DNA extracted
from the frontal cortex, brain stem, and cerebellum and
observed marked differences among the different brain
regions (Figure 3), although more samples will need to be
analyzed for consistency and a statistical analysis.Discussion
We have screened a large case and control series and devel-
oped a Southern blotting methodology to understand the
prevalence of the C9orf72 expansion and its pathogenicity
and extend genotype-phenotype correlations. Whereas
earlier studies have suggested a healthy control upper limit
of 30 repeats, we found that large expansions (>400
repeats) in C9orf72 are not infrequent in the UK popula-
tion (around 1 in 600 individuals). This is considerably
more prevalent than would be expected from epidemiolog-
ical studies. Surprisingly, control individual expansions
were indistinguishable from those of case samples. Despite
a wide range of sizes and smear morphologies, expansion
metrics did not differ in diagnostic categories. Finally, we
provide evidence in support of multiple mutational events
in human history.
In order to approximate the size of pathogenic expan-
sions, we developed a Southern blot methodology that
utilized a DIG-labeled oligonucleotide probe comprising
five hexanucleotide repeats (GGGGCC)5. Our concept was
that this probe with multiple hybridization sites within
the repeat expansion would give a stronger signal than350 The American Journal of Human Genetics 92, 345–353, March 7, 2013would a single-copy probe hybridiz-
ing to the restriction fragment con-
taining the repeats. The choice of
two frequently cutting restriction
endonucleases with restriction sites
that closely flank the repeat region
produced highly fragmented gDNA
(~200–300 bp modal size). This al-lowed the oligonucleotide repeat probe to have hybridiza-
tion specificity for the C9orf72 expansion. Further, our
suggestion is that blot findings should only be interpreted
in conjunction with an abnormal expansion detected by
the rpPCR method. No hybridization signal was detected
for restriction fragments above 1,700 bp in 50 controls,
allowing for unambiguous and sensitive detection of
C9orf72 expansions greater than ~275 repeats.
The refined methodology allows for sizing of as little as
1–3 mg gDNA. It also allows for a more accurate definition
of the range observed in gDNA samples extracted from
tissue. In LCL DNA from controls carrying large expan-
sions, the method detects multiple bands of variable
intensity, highlighting the pauciclonality that exists in
such lines.13,14 There might be a disparity in expansion
range between our data and those utilizing other blot
methods. This is most likely due to a combination of
factors. First, it is now apparent that DNA extracted
from cell lines is not reliable for the sizing of the expan-
sion. Second, the sensitivity of our assay increases the
range of expansion observed on the blot, whereas hybrid-
izations using single-copy probes are likely to reflect
a modal size. Third, it has been reported that some DNA
fragments containing repeats have unusual structures
and thus result in abnormal migration in agarose when
compared with more typical gDNA fragments.15 The
amount of flanking sequence in the fragment containing
the expansion might also influence structure.16 Therefore,
it remains a possibility that overall repeat number could
appear different with the use of a different Southern
methodology. As a precaution, we emphasize the relative
size of expansions rather than the exact number of
repeats. Although control and case expansions were
Figure 4. MarkedDifference in Observed Expansion Size for LCL
and Peripheral-Blood DNA
Southern blot showing data from three 58BC controls with
C9orf72 expansions for both peripheral-blood DNA and LCL
DNA. Typical LCL banding patterns can be seen and might repre-
sent pauciclonality of LCL DNA. Repeats associated with LCLDNA
are smaller in size than repeats seen in peripheral-blood DNA; the
latter repeats are similar in size to those in case DNA. The asterisk
indicates GGGGCC containing a short-tandem-repeat genome
motif unrelated to C9orf72.indistinguishable from one another, sequence differences
within the expansions remain a possibility. The single
individual with a discrete banding pattern (Figure S4)
might indicate the presence of such heterogeneity in
some C9orf72 expansions.
The prevalence of large expansions in the UK population
is intriguing. Lifetime risk of ALS has been estimated at ~1
in 430.17,18 Lifetime risk of FTLD is less well understood,
but the incidence measured in two studies was 3.5 and
4.1 per 100,000 in the 45–64 year age cohort;19,20 this is
comparable to that of ALS,21 implying a similar lifetime
risk. With the use of C9orf72-mutation frequencies based
on a recent large study and estimates of the proportion of
ALS and FTLD cases showing evidence of familial
disease,4,22,23 the lifetime risk of C9orf72-associated FTLD
or ALS is approximately 1 in 2,000. Although the uncer-
tainties in the true lifetime risk of FTLD prevent a formal
statistical comparison with the frequency of C9orf72
expansions, the estimate differs considerably from the
approximately 1 in 700 estimate of our population study.
There are several potential explanations for this discrep-
ancy: first, the lifetime risk of FTLD might in fact be
much greater than that of ALS; second, many clinical
syndromes caused by C9orf72 expansions are not diag-
nosed as FTLD or ALS; and third, the penetrance of theThe Ameexpansion is much lower than that predicted by family
studies of currently ascertained cases, perhaps because of
additional genetic risk factors. Our case screen supports
the second suggestion given that C9orf72 expansions
were found in all neurodegenerative-disease categories we
tested and a third of our case series had diagnoses other
than FTLD and/or ALS. Several of these syndromes (notably
Alzheimer-type dementia) are highly prevalent conditions
in old-age populations, whichmight therefore harbor large
numbers ofC9orf72 cases. These data emphasize the poten-
tial importance of the C9orf72 expansion in neurodegene-
ration in that our estimates suggest that there might be
approximately 90,000 mutation carriers in the UK.
Although the presence and size of C9orf72 expansions
did not differ between diagnostic groups, we did identify
a correlation between the age of onset and expansion
size. From three brain regions in two cases, we also found
evidence of marked and consistent differences within an
individual, indicating considerable scope for heterogeneity
in specific cell types; large smears and variable patterns
were seen in blood-extracted DNA. These findings are
likely to be due to somatic instability. Variation in expan-
sion size between brain regions and with age is consistent
with the age-dependent expansions displayed in trans-
genic mouse models of the human FXN locus;24 these
models also implicate somatic mutation. This might be
an explanation for the phenotypic heterogeneity and
incomplete penetrance of C9orf72-expansion diseases.
The considerable instability of the expansion suggested
by somatic mutation and in the CEPH families raises ques-
tions about the hypothesis regarding a single ancestral
mutational event.4,10 We used genotyping of the surrogate
marker rs3849942 for the haplotype associated with
expansions to make inferences about the stability and
origin of the expansion in UK population history. In
keeping with previous reports, we found a distinct
difference between the size distribution of repeats in
controls linked with rs3849942A and those in controls
linked with rs3849942G; longer repeats were linked to
rs3849942A.2 Additionally, all 11 control samples with
expansions greater than 400 repeats were either hetero-
zygous or homozygous for rs3849942A. In the CEPH
pedigrees, we found threemutations of repeat size between
generations, and the fact that all occurred on the
rs3849942A haplotype further indicates that the repeat
region on this haplotype is less stable. Further, using mi-
crosatellite analysis, we found no evidence of recent shared
ancestry in the UK. Two of the microsatellites genotyped
were within 300 kb of C9orf72 and would be expected to
show residual LD if a single mutational event in Finland re-
sulted in a large proportion of UK cases. Taken together,
our data are compatible with the hypothesis that larger
but normal-range repeats, which are more unstable, have
generated very large expansion mutations in unrelated
individuals many times in human history. This hypothesis
is compatible with the considerable prevalence of muta-
tions in countries distant from Finland.25rican Journal of Human Genetics 92, 345–353, March 7, 2013 351
The absence of a strong correlation between expansion
size and key aspects of the clinical phenotype was sur-
prising. In the gain-of-function model of disease etiology,
perhaps related to the sequestering of RNA binding
proteins in RNA foci, it might be expected that larger
expansions would result in a more severe phenotype.
There are several possible explanations for the lack of
such effects in our data: (1) a false-negative association
might be due to small sample size or the inability (in
many cases) to analyze tissue directly from the principle
site of pathology, (2) the clinical phenotype might be
modified by other genetic, environmental, or stochastic
factors, and (3) if the loss-of-function hypothesis is correct,
there might be complete loss of expression of C9orf72
beyond a certain expansion size.3
In summary, we have developed a reliable method of
approximating the C9orf72 expansion size, and it might
have clinical diagnostic utility. Our data emphasize the
importance of this mutation in neurodegeneration and
common neurodegenerative-disease syndromes outside
of the FTLD and ALS spectrum and provide direct evidence
of repeat instability, somatic mutation, andmultiple muta-
tional events in unrelated individuals.Supplemental Data
Supplemental Data include four figures and three tables and can
be found with this article online at http://www.cell.com/AJHG.Acknowledgments
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